BOLT

Bolt Biotherapeutics' stock has experienced a price decline, with a 33.05% decrease over the past year and a 14.6% fall since the beginning of 2026. The stock underwent a 1-for-20 reverse split on June 9th, 2025. The company announced a delay in initial clinical data for its BDC-4182 Phase 1 dose escalation study until the third quarter of 2026, attributed to modifying the trial protocol, and implemented a workforce reduction of approximately 50% to extend its cash runway into 2027. The company reported its third-quarter 2025 financial results on November 12, 2025, with collaboration revenue of $2.2 million and a reduced R&D expense. On March 12, 2026, Bolt Biotherapeutics reported its fourth-quarter and full-year 2025 financial results and also reported a Q1 2026 loss, but topped revenue estimates.